Role of gene signatures combined with pathology in classification of oropharynx head and neck cancer

[1]  J. Bussink,et al.  Inhibition of CD4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas. , 2019, International journal of radiation oncology, biology, physics.

[2]  Jacob G. Scott,et al.  Guidelines for using sigQC for systematic evaluation of gene signatures , 2019, Nature Protocols.

[3]  Jing Wang,et al.  Variations in HPV function are associated with survival in squamous cell carcinoma. , 2019, JCI insight.

[4]  B. Panizza,et al.  Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer. , 2018, Oral oncology.

[5]  P. Harari.  Why So Challenging to Personalize Radiation Dose? , 2017, International journal of radiation oncology, biology, physics.

[6]  Lihong Qi,et al.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[7]  R. Fisher,et al.  Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). , 2017, International journal of radiation oncology, biology, physics.

[8]  Brian O'Sullivan,et al.  Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[9]  A. Michaelidou,et al.  Outcomes of intensity‐modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma – a European singleinstitution analysis , 2017, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[10]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[11]  Jonathan R. Clark,et al.  Rising prevalence of human papillomavirus–related oropharyngeal cancer in Australia over the last 2 decades , 2016, Head & neck.

[12]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[13]  M. Scholz,et al.  The role of HPV RNA transcription, immune response‐related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer , 2015, International journal of cancer.

[14]  A. Harris,et al.  MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer. , 2015, International journal of radiation oncology, biology, physics.

[15]  Dong-Myung Shin,et al.  HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. , 2015, Carcinogenesis.

[16]  J. Ringash,et al.  Survivorship and Quality of Life in Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Felix Y. Feng,et al.  Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer , 2015, Clinical Cancer Research.

[18]  P. Blanchard,et al.  Treatment de‐escalation in HPV‐positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives , 2015, International journal of cancer.

[19]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[20]  P. Lambert,et al.  Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Petar Stojanov,et al.  Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas , 2014, Clinical Cancer Research.

[22]  E. Sturgis,et al.  Epidemiology of HPV-associated oropharyngeal cancer. , 2014, Oral oncology.

[23]  M. Harigopal,et al.  Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)? , 2013, International journal of radiation oncology, biology, physics.

[24]  P. Harari,et al.  Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.

[25]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[26]  T. Grob,et al.  HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  Christopher R. Cabanski,et al.  Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes , 2013, PloS one.

[28]  Sang Cheol Kim,et al.  Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells , 2012, BMC Genomics.

[29]  Yoko Yamamoto,et al.  Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. S. Sørensen,et al.  Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. , 2011, Cancer research.

[31]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[32]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[34]  J. Ragoussis,et al.  hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer , 2010, Cancer.

[35]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[36]  Crispin J. Miller,et al.  Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene , 2010, British Journal of Cancer.

[37]  M. Kokoska,et al.  Increased Microsatellite Instability and Epigenetic Inactivation of the Hmlh1 Gene in Head and Neck Squamous Cell Carcinoma , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[38]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[39]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[40]  A. Chaturvedi,et al.  Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  John N Weinstein,et al.  Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. , 2008, Cancer research.

[42]  M. Newton,et al.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. , 2007, Cancer research.

[43]  S. Takada,et al.  Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability , 2006, Oncogene.

[44]  M. J. van de Vijver,et al.  Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. , 1998, International journal of radiation oncology, biology, physics.

[45]  M. Ramam,et al.  The Background of Structure and Function , 1940 .

[46]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.